Trial Profile
A study to evaluate Galantamine transdermal (NAL8801) for the treatment of Alzheimer's disease
Status:
Not yet recruiting
Phase of Trial:
Phase I
Latest Information Update: 16 Aug 2016
Price :
$35
*
At a glance
- Drugs Galantamine (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- 16 Aug 2016 New trial record